Chemo-immunotherapy of ovarian cancer in a murine tumour model

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2585-2592

  Klimp, Alida H ^a   De Vries, Elisabeth G E ^a   Scherphof, Gerrit L ^a   Daemen, Toos ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cisplatin; GM CSF; MTP PE; Murine ovarian tumour; Peritoneal macrophages

Indexed keywords

CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM CELL; PRIORITY JOURNAL; SURVIVAL TIME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL SURVIVAL; CISPLATIN; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C3H; NITRIC OXIDE; OVARIAN NEOPLASMS; PHOSPHATIDYLETHANOLAMINES;

EID: 0033859099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hoskins WJ: Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl 23: 189-199, 1995.
2. Schink JC: Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 26: 2-7, 1999.
3. Vray B/Plasman N: Separation of murine peritoneal macrophages using Percoll density gradients. J Immunol Methods 174: 53-59, 1994.
4. Bos HJ, Boorsma DM, Tuk CW, De Veld JC, Van der Muysenberg AJ, Helmerhorst TJ, Struijk DG, Van Bronswijk H and Beelen RH: Chemotaxis of the peritoneal cells and the detection of a chemo-attractant in the effluent from peritoneal dialysis patients. Eur J Clin Invest 20: 555-562, 1990.
5. Fieren MW, Van den Bemd GJ, and Bonta IL: Endotoxin-stimulated peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients show an increased capacity to release interleukin-1 beta in vitro during infectious peritonitis. Eur J Clin Invest 20: 453-457, 1990.
6. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S, Conlon Pj: Induction of macophage tumoricidal activity by Granulocyte-Macrophage Colony-Stimulating factor. Science 232: 506-508, 1986.
7. Selgas R, Decastro MF, Jimenez C, Carcamo C, Contreras T, Bajo MA, Vara F, Corbi A: Immunomodulation of peritoneal macrophages by granulocyte-macrophage colony-stimulating factor in humans. Kidney Int 50: 2070-2078, 1996.
8. Malik STA, Martin D, Hart I, Balkwill F: Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phophoethanolamine (MTP-PE) and recombinant GM-CSF. Br J Cancer 63: 399-403, 1991.
9. Dinney, CP, Tanguay S, Bucana CD, Eve BY, Fidler U: Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice. J Interferon Cytokine Res 15: 585-592, 1995.
10. Fidler IJ: Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis. Res Immunol 143: 199-204, 1992.
11. Metcalf D, Begley CG, Williamson DJ, Nice EC, De Lamarter J, Mermod J, Thatcher D: Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. Exp Hematol 15: 1-9, 1987.
12. Williams MA, Newland AC, Kelsey SM: Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br J Haematol 98: 960-968, 1997.
13. Nagler A, Shur I, Barak V, Fabian I: Granulocyte-macrophage colony- stimulating factor dependent monocyte-mediated cytotoxicity post- autologous bone marrow transplantation. Leuk Res 20: 637-643, 1996.
14. Kleinerman, ES: Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 9: 927-938, 1995.
15. Hoedemaker RMJ, Scherphof GL, Daemen T: Repeated intravenous administration of liposome-encapsulated muramyl tripeptide-phosphatidyl ethanolamine diminshes cytotoxic potential of subpopulations of rat liver macrophages. J Liposome Res 5: 581-603, 1995.
16. Balthasar JP, Fung HL: Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Life Sci 55: 535-543, 1996.